An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor-Reference-Cited by-同舟云学术

An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor

Published:2019-06 Issue:3 Volume:153 Page:541-548
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Gore Martin,Hackshaw Allan^ORCID,Brady William E.,Penson Richard T.,Zaino Richard,McCluggage W. Glenn,Ganesan Raji,Wilkinson Nafisa,Perren Timothy,Montes Ana,Summers Jeffrey,Lord Rosemary,Dark Graham,Rustin Gordon,Mackean Melanie,Reed Nicholas,Kehoe Sean,Frumovitz Michael,Christensen Helen,Feeney Amanda,Ledermann Jonathan,Gershenson David M.

Funder

NIHR Clinical Research Network

University College London

University College London Hospital Biomedical Research Centre

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference43 articles.

1. Updates and emerging therapies for rare epithelial ovarian cancers: one size no longer fits all;Groen;Gynecol. Oncol.,2015

2. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin;Seidman;Int. J. Gynecol. Pathol.,2004

3. Differences in tumor type in low-stage versus high-stage ovarian carcinomas;Köbel;Int. J. Gynecol. Pathol.,2010